Amplification and Suppression of Distinct Brain-wide Activity Patterns by Catecholamines

Rl van den Brink, Sander Nieuwenhuis, Tobias H. DonnerbioRxiv 2018 · DOI

TL;DR

This study challenges the idea that catecholamines (like dopamine and norepinephrine) affect brain networks uniformly. Using fMRI, researchers found that atomoxetine, a drug that increases catecholamine levels, selectively amplified or suppressed specific patterns of brain activity, and these patterns closely matched the distribution of different catecholamine receptors in the brain. This suggests that the brain's complex network dynamics are finely tuned by the specific locations and types of these crucial neurotransmitter receptors.

What Problem Does This Paper Address?

For a long time, the prevailing view in neuroscience was that neuromodulators like dopamine and norepinephrine, due to their widespread release throughout the brain, exert a generally uniform influence on neural activity and network dynamics. This "homogenous modulation" hypothesis suggests that these chemicals broadly boost neural gain, enhancing signal-to-noise ratios across the entire forebrain. However, this view doesn't fully account for the fact that the brain possesses a diverse array of catecholamine receptors, each with distinct functional effects and a non-uniform distribution across different brain regions. This paper tackles the question: Are the effects of catecholamines on large-scale brain networks truly homogenous, or are they more spatially specific, reflecting the underlying receptor architecture?

Methods

The researchers re-analyzed fMRI data from a previous study where participants received either atomoxetine or a placebo. They employed a sophisticated generalized eigenvalue decomposition technique. This method is designed to identify spatial patterns of correlated brain activity (functional networks) that show differential fluctuations between two conditions (in this case, atomoxetine vs. placebo). Unlike traditional methods that might rely on pre-defined network structures, this approach directly extracts patterns that are most strongly influenced by the drug.

Key steps included:

  • Z-scoring time series data to standardize signal fluctuations.
  • Computing covariance matrices for both placebo and atomoxetine conditions.
  • Applying generalized eigenvalue decomposition to these matrices to extract "spatial modes" – patterns of brain regions that covary together and whose fluctuations differ between conditions.
  • Cross-validation and Receiver Operating Characteristic (ROC) analysis to assess the reliability and consistency of these spatial modes within individual subjects and across short data segments.
  • Spatial correlation analyses to compare the identified spatial modes with maps of catecholamine receptor gene expression from post-mortem brain data.

Datasets

The study utilized fMRI data from a previously published experiment involving 24 healthy human participants (19 females, 5 males) undergoing a double-blind, placebo-controlled crossover design with atomoxetine.

Additionally, they used a publicly available dataset from the Allen Brain Institute (Hawrylycz et al., 2012; Hawrylycz et al., 2015) which contains post-mortem microarray transcriptional profiling data from 6 individuals. This dataset provided spatial maps of gene expression, specifically focusing on catecholamine receptors, acetylcholine receptors (as a reference), and NMDA receptors.

Key Insights and Ideas

  • Catecholamine effects are spatially specific, not homogenous: The study provides strong evidence against the long-held assumption of uniform catecholaminergic effects. Instead, these neuromodulators sculpt distinct patterns of brain activity.
  • Two opposing spatial modes emerge: Atomoxetine administration led to two primary patterns of change in brain activity: one where correlations were amplified ("atomoxetine > placebo") and another where they were suppressed ("placebo > atomoxetine").
  • Receptor distribution is key: The spatial organization of these amplified and suppressed activity patterns remarkably mirrored the known distribution of specific catecholamine receptor genes in the brain. This is a crucial link between molecular-level receptor expression and macro-scale network dynamics.
  • D2-like dopamine receptors linked to enhancement: The pattern of increased correlations under atomoxetine was specifically associated with the expression of D2-like dopamine receptors.
  • Alpha-1 norepinephrine receptors linked to suppression: Conversely, the pattern of decreased correlations was linked to the expression of alpha-1 norepinephrine receptors.
  • Beta-norepinephrine receptors show mixed association: Beta-norepinephrine receptors were associated with both patterns, but with opposite signs, highlighting their complex role.
  • Specificity beyond catecholamines: The observed spatial modes showed significant associations only with catecholamine receptors, not with acetylcholine or NMDA receptors, underscoring the specificity of these findings.

Key Results

  • The generalized eigenvalue decomposition successfully identified two distinct spatial modes of brain activity that were significantly modulated by atomoxetine.
  • The "atomoxetine > placebo" spatial mode (increased correlations) showed a significant positive correlation with the spatial distribution of D2-like dopamine receptor gene expression and beta-norepinephrine receptor gene expression.
  • The "placebo > atomoxetine" spatial mode (decreased correlations) showed a significant positive correlation with the spatial distribution of alpha-1 norepinephrine receptor gene expression and a negative correlation with beta-norepinephrine receptor gene expression.
  • These associations were specific to catecholamine receptors, with no significant correlations found for acetylcholine or NMDA receptor gene expression maps.
  • Control analyses confirmed the reliability and specificity of these findings, ruling out session-related effects, artifacts, or peripheral physiological changes as explanations.

Limitations and Future Work

Limitations: * The study used a specific parcellation scheme (AAL atlas) for initial analyses, although results were validated with a different atlas (Craddock). The authors acknowledge that different parcellation schemes might yield slightly different spatial modes. * The generalized eigenvalue decomposition approach is primarily suited for comparing two conditions, limiting its direct application to more complex experimental designs (e.g., longitudinal studies with multiple time points). * The focus on the first spatial mode, while justified by its prominence and robustness, means that other potentially meaningful modes might have been less emphasized.

Future Work: * The authors suggest that their findings provide crucial constraints for developing more realistic computational models of neuromodulatory effects on large-scale brain networks. * The observed shift in frontoparietal network dominance from left-lateralized to right-lateralized under atomoxetine, and its potential link to goal-oriented stimulus processing, is highlighted as a hypothesis for future testing. * Further research could explore how these spatially specific catecholaminergic effects contribute to individual differences in cognitive function and behavior, particularly in relation to task performance.

Summary updated

Abstract

ABSTRACT The widely projecting catecholaminergic (norepinephrine and dopamine) neurotransmitter systems profoundly shape the state of neuronal networks in the forebrain. Current models posit that the effects of catecholaminergic modulation on network dynamics are homogenous across the brain. However, the brain is equipped with a variety of catecholamine receptors with distinct functional effects and heterogeneous density across brain regions. Consequently, catecholaminergic effects on brain-wide network dynamics might be more spatially specific than assumed. We tested this idea through the analysis of functional magnetic resonance imaging (fMRI) measurements performed in humans (19 females, 5 males) at ‘rest’ under pharmacological (atomoxetine-induced) elevation of catecholamine levels. We used a linear decomposition technique to identify spatial patterns of correlated fMRI signal fluctuations that were either increased or decreased by atomoxetine. This yielded two distinct spatial patterns, each expressing reliable and specific drug effects. The spatial structure of both fluctuation patterns resembled the spatial distribution of the expression of catecholamine receptor genes: α 1 norepinephrine receptors (for the fluctuation pattern: placebo > atomoxetine), ‘D2-like’ dopamine receptors (pattern: atomoxetine > placebo), and β norepinephrine receptors (for both patterns, with correlations of opposite sign). We conclude that catecholaminergic effects on the forebrain are spatially more structured than traditionally assumed and at least in part explained by the heterogeneous distribution of various catecholamine receptors. Our findings link catecholaminergic effects on large-scale brain networks to low-level characteristics of the underlying neurotransmitter systems. They also provide key constraints for the development of realistic models of neuromodulatory effects on large-scale brain network dynamics. SIGNIFICANCE STATEMENT The catecholamines norepinephrine and dopamine are an important class of modulatory neurotransmitters. Because of the widespread and diffuse release of these neuromodulators, it has commonly been assumed that their effects on neural interactions are homogenous across the brain. Here, we present results from the human brain that challenge this view. We pharmacologically increased catecholamine levels and imaged the effects on the spontaneous covariations between brain-wide fMRI signals at ‘rest’. We identified two distinct spatial patterns of covariations: one that was amplified and another that was suppressed by catecholamines. Each pattern was associated with the heterogeneous spatial distribution of the expression of distinct catecholamine receptor genes. Our results provide novel insights into the catecholaminergic modulation of large-scale human brain dynamics.
BibTeX
@misc{brink2018amplification,
  author = {RL van den Brink and Sander Nieuwenhuis and Tobias H. Donner},
  title = {{Amplification and Suppression of Distinct Brain-wide Activity Patterns by Catecholamines}},
  year = {2018},
  doi = {10.1101/270645},
  howpublished = {bioRxiv},
}
Figure